ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Proteases >Proteasome inhibitors >CEP-18770

CEP-18770

CAS No.: 847499-27-8

Chemical Name:: CEP-18770

Synonyms: CS-252;CT 47098;CEP-18770;CIP 18770;NPH 007098;Delanzomib;Delanzomib, >=98%;CEP-18770 (DelanzoMib);DelanzoMib (CEP-18770);Delanzomib, 10 mM in DMSO

CBNumber:: CB42570998

Molecular Formula:: C21H28BN3O5

Molecular Weight:: 413.28

MOL File:: 847499-27-8.mol

Modify Date:: 2025/4/17 18:22:24

Request For Quotation

CEP-18770 Properties

Melting point	178-190°C (dec.)
Density	1.207
storage temp.	Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility	Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
form	Solid
pka	9.67±0.43(Predicted)
color	White to Off-White
Stability	Hygroscopic

SAFETY

Risk and Safety Statements

HS Code	29333990

CEP-18770 Chemical Properties,Uses,Production

Description

Delanzomib is an orally bioavailable inhibitor of chymotrypsin-like proteasome activity (IC₅₀ = 3.8 nM in isolated human erythrocytes) that only marginally inhibits tryptic and peptidyl glutamyl proteasome activity. Delanzomib pre-treatment (20 nM) in vitro inhibits IκBα degradation, NF-κB activation, and the expression of NF-κB-regulated genes, including IκBα, XIAP, TNF-α, IL-1β, ICAM-1, and VEGF. Delanzomib induces apoptosis in multiple myeloma cell lines and inhibits proliferation in a panel of human hematologic and solid tumor cell lines (IC₅₀s = 5.6-34.2 nM). It reduces tumor weight in an RPMI 8226 human multiple myeloma mouse xenograft model when administered intravenously at doses ranging from 1.5-4 mg/kg twice daily and leads to complete tumor regression at a chronic oral dose of 13 mg/kg. Delanzomib reduces the serum level of circulating cytokines, prevents renal tissue damage, and increases lifespan in a mouse model of fatal lupus nephritis.

Uses

Delanzomib is an orally active proteasome inhibitor. Delanzomib has been shown to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.

CEP-18770 Preparation Products And Raw materials

Raw materials

Preparation Products

CEP-18770 Suppliers

Global( 126)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
career henan chemical co	+86-0371-86658258 +8613203830695	China	29808	58	Inquiry
SIMAGCHEM CORP	+86-13806087780	China	17365	58	Inquiry
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	United States	32159	58	Inquiry
Win-Win chemical CO., Limited	+86-0086-577-64498589 +86-15355981851	China	14442	58	Inquiry
AFINE CHEMICALS LIMITED	+86-0571-85134551	China	15395	58	Inquiry
Baoji Guokang Bio-Technology Co., Ltd.	0917-3909592 13892490616	China	9304	58	Inquiry
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	China	10473	58	Inquiry
Nextpeptide Inc	+86-0571-81612335 +8613336028439	China	19908	58	Inquiry
Guangzhou TongYi biochemistry technology Co.,LTD	+8613073028829	China	2994	58	Inquiry
InvivoChem	+1-708-310-1919 +1-13798911105	United States	6391	58	Inquiry

Supplier	Advantage
career henan chemical co	58
SIMAGCHEM CORP	58
TargetMol Chemicals Inc.	58
Win-Win chemical CO., Limited	58
AFINE CHEMICALS LIMITED	58
Baoji Guokang Bio-Technology Co., Ltd.	58
Zhejiang J&C Biological Technology Co.,Limited	58
Nextpeptide Inc	58
Guangzhou TongYi biochemistry technology Co.,LTD	58
InvivoChem	58

CEP-18770 Spectrum

CEP-18770(847499-27-8)¹HNMR

847499-27-8(CEP-18770)Related Search:

CPI-455 Maritoclax GDC-0623 IMR-1 CHIR 99021 trihydrochloride

LJI308 2-((2-Chlorophenyl)(phenyl)aMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide AZ191 HTH-01-015 GDC-0879

4-iodo-3-nitrobenzamide VBY-825 Bortezomib MLN9708 MK-2206 2HCl

(R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid Oprozomib Carfilzomib

chevron_left

1of4

chevron_right

CEP-18770 [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid CIP 18770 CT 47098 Delanzomib NPH 007098 CEP-18770 (DelanzoMib) DelanzoMib, Free Base, >99% ((R)-1-((2S,3R)-3-Hydroxy-2-(6-phenylpicolinaMido)butanaMido)-3-Methylbutyl)boronic acid (R)-1-((2S,3R)-3-hydroxy-2-(2-phenylpicolinamido)butanamido)-3-methylbutan-2-ylboronic acid Delanzomib [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid Delanzomib, >=98% DelanzoMib (CEP-18770) Boronic acid, B-[(1R)-1-[[(2S,3R)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]aMino]butyl]aMino]-3-Methylbutyl]- (1R)-1-[(2S,3R)-3-hydroxy-2-[(6-phenylpyridin-2-yl)formamido]butanamido]-3-methylbutyl]boronic acid CS-252 CEP-18770;CEP 18770;CEP18770 ((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid Delanzomib, 10 mM in DMSO 847499-27-8 C21H28BN3O5 Inhibitor Inhibitors